dc.contributor.author | Ocio San Miguel, Enrique María | es_ES |
dc.contributor.author | Bringhen, Sara | es_ES |
dc.contributor.author | Martinez-Lopez, Joaquin | es_ES |
dc.contributor.author | San-Miguel, Jesus | es_ES |
dc.contributor.author | Oliva, Stefania | es_ES |
dc.contributor.author | Rodriguez-Otero, Paula | es_ES |
dc.contributor.author | Le Roux, Nadia | es_ES |
dc.contributor.author | Dong, Yvonne | es_ES |
dc.contributor.author | Doroumian, Severine | es_ES |
dc.contributor.author | Macé, Sandrine | es_ES |
dc.contributor.author | Mateos, Maria-Victoria | es_ES |
dc.contributor.other | Universidad de Cantabria | es_ES |
dc.date.accessioned | 2023-09-12T16:44:52Z | |
dc.date.available | 2023-09-12T16:44:52Z | |
dc.date.issued | 2023 | es_ES |
dc.identifier.issn | 2572-9241 | es_ES |
dc.identifier.uri | https://hdl.handle.net/10902/29876 | |
dc.format.extent | 5 p. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Wolters Kluwer Health | es_ES |
dc.rights | Attribution-NonCommercial-ShareAlike 4.0 International | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-sa/4.0/ | * |
dc.source | HemaSphere, 2023, 7(2), e829 | es_ES |
dc.title | Phase 1b study of isatuximab in combination with bortezomib, cyclophosphamide, and dexamethasone in newly diagnosed, transplant-ineligible multiple myeloma patients. | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.rights.accessRights | openAccess | es_ES |
dc.identifier.DOI | 10.1097/HS9.0000000000000829 | es_ES |
dc.type.version | publishedVersion | es_ES |